Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05193474
Other study ID # 202106064RINB
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date August 31, 2023

Study information

Verified date August 2021
Source National Taiwan University Hospital
Contact Pei-Ni Chuang, M.D.
Phone +886-987-650-338
Email peinichuang@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical research study is to study the cardiopulmonary resuscitation (CPR) preferences of patients receiving peritoneal dialysis and how these preferences are associated with their responses to questions about aspects of end-of-life care. This prospective cohort clinical trial aims to provide evidence on the preferences of end of life care in patients receiving peritoneal dialysis, thereby provide optimal care according to patients' preferences and choices through effective communication and clear goals of care.


Description:

This is a prospective cohort study to survey cardiopulmonary resuscitation (CPR) preferences of patients receiving peritoneal dialysis and how these preferences are associated with their responses to questions about aspects of end-of-life care for end stage renal disease(ESRD) patients, and actively survey their palliative care need to share decision making with ESRD patient whether to receive standardized palliative care interventions by the interdisciplinary palliative care team, including treatment of suffering symptoms, non-pharmacologic therapies. The investigators will enroll 500 patients. The eligibility criteria are shown later part. After obtaining consent from the patient, the investigators will conduct baseline assessments and start the patient on a 10minutes questionnaire. The questionnaire was cited from 2016-CA-POLST, which is in Chinese version for better understanding. POLST is an approach to end-of-life planning based on conversations between patients, loved ones, and health care professionals designed to ensure the patient only receive the care that patients themselves wish to. After that, the investigators will active survey the patient who had higher mortality rate within one year by using 1. Palliative Care Screening Tool (PCST), 2."Surprise" Question,3. Integrated model risk≥10%. For the patient who had higher mortality rate within one year (>10%), the investigators would evaluate the degree of symptoms burden by using ESAS-r: Renal. For the patient who had moderate to severe symptoms burden, the investigators would share decision making with them to discuss whether to receive combined palliative care. The investigators would divide the patients to two group according to patient decision. (1) Usual ESRD care team (2) Usual ESRD care + combined palliative care team. And the investigators would compare the quality of life and quality of death, and symptoms burden after 3/6/12 months receiving timely integrated palliative care to the other group Evaluate outcomes including quality of life (EQ-5D-5L), quality of death (GDS), symptoms burden(ESAS-r:Renal)


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date August 31, 2023
Est. primary completion date February 1, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. [Patients] Diagnosis of ESRD 2. [Patients] Under treatment of peritoneal dialysis 3. [Patients] Age 20 years or older 4. [Caregivers] Age20 years or older Exclusion Criteria: - [Patients] unable to understand or fill in the questionnaire

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
integrated palliative care
shared decision making with patient, and timely integrated palliative care according to patient's preference

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary the preferences of end of life care in patients receiving peritoneal dialysis Participants were asked to respond to the questions(POLST questionnaire) associated to life-sustaining treatment preference including CPR preference and other treatment preferences, and life values, up to 24 weeks
Secondary compare the quality of life after receiving timely integrated palliative care to the other group Quality of life(The EuroQol-5 Dimension 5-level (EQ-5D-5L)) The EQ-5D instrument is the most widely used generic preference-based measure of health.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
3 moths,6 months and 12months after receiving timely integrated palliative care
Secondary compare the quality of death after receiving timely integrated palliative care to the other group Quality of death(Good Death Scale (GDS)) Good Death Scale (GDS) is a provider assessment scale of the quality of dying of terminally ill patients. It contains 5 items including the awareness that one is dying (0 = complete ignorance, 3 = complete awareness), accepting death peacefully (0 = complete unacceptance, 3 = complete acceptance), propriety (0 = no reference to the patient's will, 1 = following the family's will alone, 2 = following the patient's will alone, 3 = following the will of both the patient and their family), death timing (0 = no preparation, 1 = the family alone had prepared, 2 = the patient alone had prepared, 3 = both the patient and their family had prepared), and degree of physical comfort (0 = a lot of suffering, 1 = suffering, 2 = a little suffering, 3 = no suffering). The score ranges from 0 to 15. 3 moths,6 months and 12months after receiving timely integrated palliative care
Secondary compare the symptoms burden after receiving timely integrated palliative care to the other group Symptoms burden(Edmonton Symptom Assessment System. Revised Renal (ESAS-r:Renal)) The ESAS-r helps to assess nine common symptoms in palliative care patients. The ESAS-r is one valuable part of a holistic clinical assessment. It is not a complete assessment in itself. The patient should be instructed to rate the severity of each symptom on a 0 to 10 scale, where 0 represents absence (or best possible intensity) of the symptom and 10 represents the worst possible severity. The number should be circled on the scale.
The circled numbers can be transcribed onto the ESAS-r graph. The patient should be instructed to rate each symptom according to how s/he feels now. The health care professional may choose to ask additional questions about the severity of symptoms at other time points (e.g. symptom severity at best and at worst over the past 24 hours)
3 moths,6 months and 12months after receiving timely integrated palliative care
Secondary compare the ICU admission frequency after receiving timely integrated palliative care to the other group ICU admission frequency 3 moths,6 months and 12months after receiving timely integrated palliative care
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03943212 - The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis N/A
Completed NCT03456648 - Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study Phase 2
Completed NCT01252771 - Phosphate Kinetic Modeling 2 Phase 4
Completed NCT00966615 - The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition Phase 4
Completed NCT00850252 - Use of a Lifeline Graft in the A-V Shunt Model Phase 1/Phase 2
Completed NCT00294502 - Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia Phase 4
Completed NCT05011136 - Physician Reimbursement Home Patients
Completed NCT05144971 - StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Completed NCT02278562 - Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2 Phase 2
Completed NCT01424787 - Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering) N/A
Terminated NCT00580762 - Bariatric Surgery for ESRD Patients vs Control N/A
Recruiting NCT05339139 - SAfety of Regional Citrate Anticoagulation (SARCA Study) Phase 3
Completed NCT03242343 - VasQ External Support for Arteriovenous Fistula N/A
Recruiting NCT05309785 - Safety and Efficacy of Canagliflozin in Advanced CKD Phase 4
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Not yet recruiting NCT02596386 - Examination of Potassium Levels in Saliva in ESRD Patients N/A
Active, not recruiting NCT02270515 - Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease N/A
Recruiting NCT06001827 - SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study N/A